Listing & Compliance Notices

ENZO BIOCHEM INC received a nyse noncompliance notice notice regarding market value (rules 802.01B, 802.01C).

“January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because as of January 7, 2025, the Company’s 30 trading-day average market capitalization was less than $50 million and its last reported stockholder’s equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Common Stock (the “Common Stock”) was less than $1.00 ove”

ENZO BIOCHEM INC received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma”

ENZO BIOCHEM INC received a nyse deficiency notice notice regarding market value (rules 802.01B).

“January 8, 2025 Enzo Biochem, Inc. (the “Company”) received a letter from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Ma”

Nature's Miracle Holding Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“January 13, 2025, Nature’s Miracle Holding Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s s”

PHOENIX MOTOR INC. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 10, 2025, Phoenix Motor Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), which stated that the Company no longer complies with Nasdaq’s continued listing rules due to the Compan”

Evolution Metals & Technologies Corp. received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“December 31, 2024, Welsbach Technology Metals Acquisition Corp., (the “Company” or “WTMA”) received a letter (the “Notice”) from the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stat”

CISO Global, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, CISO Global Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company has not yet held an ann”

ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“January 9, 2025, ABVC BioPharma, Inc. (the "Company") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550(a)(2) (the “Rule”). On July 12, 2024, the Company disclosed that Nasdaq had informed it that its stock had failed to maintain the minimum bid price over the preceding 30 business days. At that time, the Company was given until January 6, 2025, to regain compliance. The current extension was granted based on the Company’s adherence to other l”

LIPELLA PHARMACEUTICALS INC. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1)).

“January 10, 2025, Lipella Pharmaceuticals Inc. (the “Company”) received a decision (the “January Letter”) from the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”), including the achievement of interim milestones. Specifically, the Panel granted the Company’s request for continued listing, subject to the following: (i) on or before April 14, 2025, the C”

GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“le or Standard; Transfer of Listing. On January 7, 2025, Entero Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a), due to the Company not holding an annual meeting of stockholders in 2024 within one year of the Company’s 2023 fiscal year end. The Company has until February 21, 2025, which is 45 days from the date of the Notice, to submit a plan to regain compliance and, if Nasdaq accepts the plan, it ma”

Phunware, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, Phunware, Inc. (the "Company") received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with the rules for continued listing as set forth in Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) because the Company has not held an annual meeting of stockholders within 12 months of year-end for the fiscal year ended as of December 31, 2023. Under Nasdaq rules, the Company has 45 days to submit a plan to Nasdaq to regain compliance, and if Nasdaq accepts the Company's plan, Nasdaq can grant an exception of up to 180 cale”

Distoken Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“January 7, 2025, Distoken Acquisition Corporation (the “ Company ”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that, for the preceding 32 consecutive business days, the Company’s Market Value of Listed Securities (“ MVLS ”) was below the $50 million minimum requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “ MVLS Requirement ”). The notification received has no immediate effect on the Company’s Nasdaq listing. The Nasdaq rules”

Cyclo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, Cyclo Therapeutics, Inc. (the "Company”) received a letter from The Nasdaq Stock Market ("Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for continued listing because it had not yet held an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. Pursuant to the Nasdaq Listing Rules, the Company has 45 calendar days (until February 24, 2025) to submit a plan to regain compliance with the Nasdaq Listing Rules, and if the plan is accepted, Nasdaq may grant the Company an excepti”

Cyclo Therapeutics, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, Cyclo Therapeutics, Inc. (the "Company”) received a letter from The Nasdaq Stock Market ("Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for”

Distoken Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“January 7, 2025, Distoken Acquisition Corporation (the “ Company ”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that”

Phunware, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 10, 2025, Phunware, Inc. (the "Company") received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with the rules for continued listing as set forth”

GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a), due to the Company not holding an annual meeting of stockholders in 2024 within one year of the Compa”

LIPELLA PHARMACEUTICALS INC. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1), 5550(a)(2)).

“January 10, 2025, Lipella Pharmaceuticals Inc. (the “Company”) received a decision (the “January Letter”) from the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s requ”

ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“January 9, 2025, ABVC BioPharma, Inc. (the "Company") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as”

Clean Energy Technologies, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 8, 2025, Clean Energy Technology, Inc., a Nevada corporation (the “ Company ”) received a letter from the staff of the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) for continued listing of shares of the Company’s common stock, par value $0.001 per share, due to the Company’s failure to hold an annual meeting within 12 months of the end of the Company’s fiscal year ended December 31, 2023. As a result, as of January 8, 2025, the Company has 45”

Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“January 6, 2025, Carisma Therapeutics Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of its common stock for the last 38 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”), which requires the Company to maintain a minimum bid price of $1.00 per share. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or t”

NEUROONE MEDICAL TECHNOLOGIES Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 8, 2025, the Company received a letter from the Staff indicating the Company’s continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company’s common stock would be delisted from The Nasdaq Capital Market unless the Company appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company’s request for a hearing will stay any further delisting action by the Staff pending the ultimate outcome of the hearing. The Company’s common stock will remain listed and eligible”

Professional Diversity Network, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 9, 2025, the Company received a letter from Nasdaq informing the Company that the Nasdaq Staff has determined that the Company had not regained compliance with Rule 5550(a)(2), stating that the Company did not satisfy the initial listing requirements for The Nasdaq Capital Market under the equity standard or alternative standards and was consequently not eligible for an additional 180-day remediation period. Accordingly, unless the Company requests an appeal of this determination by January 16, 2025, Nasdaq has determined that the Company’s securities will be scheduled for delisting fr”

Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding other (rules 704).

“January 6, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the NYSE American LLC (“NYSE American”) stating that the Company failed to hold an annual meeting of stockholders during its fiscal year ended December 31, 2024, as required by Section 704 of the NYSE American Company Guide (the “Company Guide”). A copy of the press release that discusses this matter is furnished as Exhibit 99.1 hereto and incorporated herein by reference. The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be li”

Evofem Biosciences, Inc. received a otc deficiency notice notice regarding minimum bid price.

“January 6, 2025, Evofem Biosciences, Inc. (the “Company”) received a written notice (the “OTC Notice”) from the OTC Markets Group (“OTC”) notifying the Company that, because the closing bid price for the Company’s common stock was below $0.01 per share for 30 consecutive calendar days, the Company is not currently in compliance with the minimum bid price requirement for continued listing on OTCQB Venture Market (“OTCQB”), as set forth in the OTCQB listing standards, section 2.3 (the “Minimum Bid Price Requirement”). The OTC Notice has no immediate effect on the listing of the Company’s common”

Co-Diagnostics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 10, 2025, Co-Diagnostics, Inc. (“CODX” or “the Company”) received a notice from Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). The Company has a period of 180 calendar days, or until July 9, 2025 (the “Compliance Date”), to regain compliance with Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s com”

BONK, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 2, 2025, Safety Shot, Inc., (the “Company”) received a notice from The Nasdaq Stock Exchange (“Nasdaq”) that the closing bid price for our common stock had been below $1.00 per share for the previous 30 consecutive days, and that we are therefore not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). Nasdaq’s Notice has no immediate effect on the listing or trading of our common stock on the Nasdaq Capital Market. The notice indicates that we will have 180 calendar days, unt”

Next Technology Holding Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 7, 2025, Next Technology Holding Inc (formerly known as WeTrade Group Inc. (the “Company”)) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the rules for continued listing as set forth in Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) because the Company has not yet held an annual meeting of stockholders for the fiscal year ended as of December 31, 2023 within 12 months of the year end. The Company has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company may be”

System1, Inc. received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01C).

“January 6, 2025 System1, Inc. (the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A Common Stock ("the Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s Common Stock from the NYSE. The Company plans to notify the NYSE by January 21, 2025 that it intends to cure the average closing stock price deficiency and to return to compliance with th”

NEXTNRG, INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 10, 2025, EzFill Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer complies with Nasdaq rules for continued listing (the “Rules”) because the Company has not yet held an annual meeting of stockholders within one year after the end of the Company’s fiscal year ended December 31, 2023, as required pursuant to Rule 5620(a) of the Rules (the “Annual Meeting Requirement”). Under the Rules, the Company has 45 calendar days to submit a plan to regain compliance an”

Cartica Acquisition Corp received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“January 13, 2025 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by January 4, 2025, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company’s securities are now”

Broad Capital Acquisition Corp received a nasdaq deficiency notice notice regarding other (rules 5450(b)(2)(B)).

“January 6, 2025, Broad Capital Acquisition Corp. (the “Company”) received a letter (the “Letter”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq’s Listing Rule 5450(b)(2)(B) (the “Rule”) because the Company has not, as of December 31, 2024, maintained a minimum of 1,100,000 publicly held shares, as required under the Nasdaq continued listing standards for The Nasdaq Global Market. Under Nasdaq Listing Rules, the Company has 45 calendar days or until February 20, 2025 to submit a”

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“January 3, 2025, Incannex Healthcare Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) (the “Listing Rule”), which requires the Company to maintain a minimum Market Value of Listed Securities (“MVLS”) of at least $50.0 million. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the”

AMAZE HOLDINGS, INC. received a nyse_american deficiency notice notice regarding other (rules 704).

“January 6, 2025, Fresh Vine Wine, Inc. (the “Company”) received a letter from NYSE American LLC notifying the Company that it is not in compliance with Section 704 of the NYSE American Company Guide because the Company failed to hold an annual meeting for the fiscal year ended December 31, 2023 by December 31, 2024. The Company intends to hold a meeting of stockholders in the next several months with respect to the proposed business combination with Adifex Holdings LLC, which meeting the Company expects will bring it into compliance with Section 704. Further information about the business comb”

LUXURBAN HOTELS INC. received a nasdaq noncompliance notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 9, 2025, LuxUrban Hotels Inc. (the “Company”) received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has failed to hold its annual meeting of shareholders within twelve months following the end of its fiscal year. As a result, the Company no longer satisfies the requirements set forth under Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) (the “Listing Rules”) for continued listing. The notice further requests that the Company submit its written response regarding this additional deficiency to Nasdaq no lat”

Qomolangma Acquisition Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5550(a)(3)).

“August 26, 2024, the Company received written notice from the Listing Qualifications Staff of Nasdaq (the “Staff”) indicating that the Company no longer complied with the Nasdaq Capital Market continued listing criteria set forth in Listing Rule 5550(a)(3), which requires the Company to maintain a minimum of 300 public holders (the “Notice”). The Notice provided the Company with 45 calendar days, or until October 10, 2024, to submit a plan to regain compliance. On November 13, 2024, the Staff issued a follow-up letter to the Company advising that the Staff determined that it was unable to gran”

Sharplink, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5505(b)(1), 5810(d)(2)).

“July 11, 2024, the Company received a letter (the “Bid Price Deficiency Notice”) from Nasdaq notifying the Company that, because the closing bid price for its common stock had been below $1.00 per share for 30 consecutive trading days, it was not compliant with the Minimum Bid Price Requirement. In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company had a period of 180 calendar days, or until January 7, 2025, to regain compliance with the Minimum Bid Price Requirement. If at any time before January 7, 2025, the closing bid price of the Company’s common stock closed at or above $”

Damon Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“January 7, 2025, Damon Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive business days from November 18, 2024 to January 6, 2025, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). An indicator will be displayed with quotation information related to the Company’s”

GENCOR INDUSTRIES INC received a nyse_american noncompliance notice notice regarding late filing (rules 1007).

“January 3, 2025, the Company received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company is not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Form 10-K with the SEC prior to December 31, 2024, the end of the extension period provided by the Form 12b-25, and is now subject to the procedures set forth in Section 1007 of the NYSE American Company Guide. The NYSE informed the Company that, under the rules of the NYSE American, the Company has six months from the Fo”

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). Nasdaq Listing Rule 5810(c)(3)(C) provides a compliance period of 180 calendar days, or until July 7, 2025, in which to regain compl”

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecu”

GENCOR INDUSTRIES INC received a nyse_american deficiency notice notice regarding late filing.

“January 3, 2025, the Company received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company is not in compliance with the NYSE American LLC (“NYSE American”) continued listing”

Damon Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“January 7, 2025, Damon Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the”

LUXURBAN HOTELS INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 9, 2025, LuxUrban Hotels Inc. (the “Company”) received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has failed to hold its annual”

AMAZE HOLDINGS, INC. received a nyse_american deficiency notice notice regarding other.

“January 6, 2025, Fresh Vine Wine, Inc. (the “Company”) received a letter from NYSE American LLC notifying the Company that it is not in compliance with Section 704 of the NYSE American Company Guide because the Company f”

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“January 3, 2025, Incannex Healthcare Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company”

Broad Capital Acquisition Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5450(b)(2)(B)).

“January 6, 2025, Broad Capital Acquisition Corp. (the “Company”) received a letter (the “Letter”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the C”

Cartica Acquisition Corp received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“January 6, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (“Rule IM-5101-2”), the staff of Nas”

NEXTNRG, INC. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 10, 2025, EzFill Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer complies with”

System1, Inc. received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01C).

“January 6, 2025 System1, Inc. (the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price”